FDA Requests Eli Lilly and Novo Nordisk to Remove Suicide Warnings from GLP-1 Drug Labels
FDA; GLP-1; suicide warnings; Eli Lilly; Novo Nordisk; Wegovy; Zepbound; Saxenda
Bristol Myers Squibb Completes $4.8 Billion Acquisition of Mirati Therapeutics
Bristol Myers Squibb; Mirati Therapeutics; acquisition; $4.8 billion; KRAZATI; oncology; KRAS G12C
Novo Nordisk Refocuses on Diabetes and Obesity to Expand GLP-1 Market at JPM26
Novo Nordisk; diabetes; obesity; GLP-1; JPM26; Mike Doustdar; Wegovy pill; semaglutide
JPM26: Novo Nordisk and Eli Lilly Compete Fiercely in Oral Obesity Treatments
Novo Nordisk; Eli Lilly; oral obesity drugs; JPM26; JPMHC; orglipron; semaglutide
Lightning Step and Sunwave Achieve SOC 2 Type II Attestation, Strengthening Security and Trust Across Healthcare Technology
Lightning Step; Sunwave; SOC 2 Type II; Healthcare Technology; Security; Compliance
Sentynl Therapeutics Receives FDA Approval for ZYCUBO, First US Treatment for Rare Menkes Disease
Sentynl Therapeutics; ZYCUBO; FDA approval; Menkes disease; copper histidinate; Zydus Lifesciences
Novartis Licenses Undisclosed Radioligand Therapy Asset from China’s Zonsen PepLib Biotech
Novartis; Zonsen PepLib; radiopharma; radioligand therapy; licensing deal; China biotech
FDA Requests Flu Vaccine Label Updates for Febrile Seizure Risk in Young Children
FDA; flu vaccine; febrile seizures; label update; children; influenza vaccine
JPM26 Live Blog Day 2: GSK Stays the Course Amid Key Biopharma Updates
JPM26; GSK; J.P. Morgan Healthcare Conference; Day 2; AstraZeneca; Novo Nordisk; biotech
JPM26: BMS Highlights Early-Stage Bets and Pipeline Progress Amid Late-Stage Pharma Focus
BMS; JPM26; early-stage bets; pipeline; Cobenfy; Milvexian; Admilparant; Pumitamig; Camzyos